Evidence map›Paper›PMID 23812352›Full record

ReviewPediatric nephrology (Berlin, Germany)2014

Venous thromboembolism in pediatric nephrotic syndrome.

Bryce A Kerlin, Kellie Haworth, William E Smoyer

Open access · greenAbstract readReview
In one paragraph

Review in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Nephrotic Syndrome: Current Management.Indian journal of pediatrics · 2026
    Review
  4. Article
  5. Review
  6. Podocytopathies.Nature reviews. Disease primers · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Postoperative Intracardiac Thrombus in a Child with Nephrotic Syndrome.International medical case reports journal · 2022
    Article
  19. Rapidly progressive edema in a 3-year-old male.Paediatrics & child health · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Bryce A KerlinDepartment of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA, bryce.kerlin@nationwidechildrens.org.
Kellie Haworth
William E Smoyer
Nationwide Children's Hospital · US

Funding

Coagulation Protease Signaling in Glomerular DiseaseK08DK103982 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KERLIN, BRYCE ANDREW · 2015 to 2019
$744k
NIDDK NIH HHS K08 DK103982NIDDK NIH HHS L40 DK103299
6 · The paper itself

Abstract

Childhood nephrotic syndrome (NS) is one of the most common pediatric kidney diseases, with an incidence of 2-7 per 100,000. Venous thromboembolism (VTE) is associated with significant morbidity and mortality, and occurs in ∼3 % of children with NS, though incidence approaches 25 % in high-risk groups. VTE etiology is multifactorial, with disease-associated coagulopathy thought to be a significant contributor. Other risks include age, disease severity, and treatment-related hazards, such as the presence of central venous catheters. Non-pharmacologic preventive measures such as ambulation and compression stockings are recommended for patients with identified VTE risks. Central venous catheters should be avoided whenever possible. Symptoms of VTE include venous catheter dysfunction, unilateral extremity symptoms, respiratory compromise, flank pain, and gross hematuria. When VTE is suspected, confirmatory imaging studies should be obtained, followed by appropriate laboratory evaluation and treatment. Therapeutic goals include limiting thrombus growth, extension, and embolization by early institution of anticoagulant therapy. Anticoagulation is recommended for a minimum of 3 months, but should be continued until NS remission is achieved. Further studies are necessary to identify VTE-risk biomarkers and optimal therapeutic regimens. Observational cohort studies are needed to identify VTE-risk groups who may benefit from thromboprophylaxis and to define disease-specific treatment algorithms.

Indexed as

Venous ThromboembolismChildHumansNephrotic Syndrome

Identifiers

PMID23812352
PMCPMC6556227
OpenAlexW2076044239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.